155 related articles for article (PubMed ID: 34605158)
21. Sensitivity of human lung adenocarcinoma cell lines to targeted inhibition of BET epigenetic signaling proteins.
Lockwood WW; Zejnullahu K; Bradner JE; Varmus H
Proc Natl Acad Sci U S A; 2012 Nov; 109(47):19408-13. PubMed ID: 23129625
[TBL] [Abstract][Full Text] [Related]
22. The Bromodomain Inhibitor JQ1 and the Histone Deacetylase Inhibitor Panobinostat Synergistically Reduce N-Myc Expression and Induce Anticancer Effects.
Shahbazi J; Liu PY; Atmadibrata B; Bradner JE; Marshall GM; Lock RB; Liu T
Clin Cancer Res; 2016 May; 22(10):2534-44. PubMed ID: 26733615
[TBL] [Abstract][Full Text] [Related]
23. BET bromodomain inhibition promotes neurogenesis while inhibiting gliogenesis in neural progenitor cells.
Li J; Ma J; Meng G; Lin H; Wu S; Wang J; Luo J; Xu X; Tough D; Lindon M; Rioja I; Zhao J; Mei H; Prinjha R; Zhong Z
Stem Cell Res; 2016 Sep; 17(2):212-221. PubMed ID: 27591477
[TBL] [Abstract][Full Text] [Related]
24. The BET bromodomain inhibitor JQ1 radiosensitizes non-small cell lung cancer cells by upregulating p21.
Wang J; Wang Y; Mei H; Yin Z; Geng Y; Zhang T; Wu G; Lin Z
Cancer Lett; 2017 Apr; 391():141-151. PubMed ID: 28143717
[TBL] [Abstract][Full Text] [Related]
25. JQ1 affects BRD2-dependent and independent transcription regulation without disrupting H4-hyperacetylated chromatin states.
Handoko L; Kaczkowski B; Hon CC; Lizio M; Wakamori M; Matsuda T; Ito T; Jeyamohan P; Sato Y; Sakamoto K; Yokoyama S; Kimura H; Minoda A; Umehara T
Epigenetics; 2018; 13(4):410-431. PubMed ID: 30080437
[TBL] [Abstract][Full Text] [Related]
26. Discovery and characterization of bromodomain 2-specific inhibitors of BRDT.
Yu Z; Ku AF; Anglin JL; Sharma R; Ucisik MN; Faver JC; Li F; Nyshadham P; Simmons N; Sharma KL; Nagarajan S; Riehle K; Kaur G; Sankaran B; Storl-Desmond M; Palmer SS; Young DW; Kim C; Matzuk MM
Proc Natl Acad Sci U S A; 2021 Mar; 118(9):. PubMed ID: 33637650
[TBL] [Abstract][Full Text] [Related]
27. BCL6 confers KRAS-mutant non-small-cell lung cancer resistance to BET inhibitors.
Guo J; Liu Y; Lv J; Zou B; Chen Z; Li K; Feng J; Cai Z; Wei L; Liu M; Pang X
J Clin Invest; 2021 Jan; 131(1):. PubMed ID: 33393503
[TBL] [Abstract][Full Text] [Related]
28. Polymorphisms in Epithelial-Mesenchymal Transition-Related Genes and the Prognosis of Surgically Treated Non-small Cell Lung Cancer.
Seok Y; Kang HG; Lee SY; Jeong JY; Choi JE; Jung DK; Jin CC; Hong MJ; Do SK; Lee WK; Park JY; Shin KM; Yoo SS; Lee J; Cho S; Cha SI; Kim CH; Jheon S; Lee EB; Park JY
Ann Surg Oncol; 2017 Oct; 24(11):3386-3395. PubMed ID: 28766235
[TBL] [Abstract][Full Text] [Related]
29. Intrinsic BET inhibitor resistance in SPOP-mutated prostate cancer is mediated by BET protein stabilization and AKT-mTORC1 activation.
Zhang P; Wang D; Zhao Y; Ren S; Gao K; Ye Z; Wang S; Pan CW; Zhu Y; Yan Y; Yang Y; Wu D; He Y; Zhang J; Lu D; Liu X; Yu L; Zhao S; Li Y; Lin D; Wang Y; Wang L; Chen Y; Sun Y; Wang C; Huang H
Nat Med; 2017 Sep; 23(9):1055-1062. PubMed ID: 28805822
[TBL] [Abstract][Full Text] [Related]
30. BET inhibitors block pancreatic stellate cell collagen I production and attenuate fibrosis in vivo.
Kumar K; DeCant BT; Grippo PJ; Hwang RF; Bentrem DJ; Ebine K; Munshi HG
JCI Insight; 2017 Feb; 2(3):e88032. PubMed ID: 28194432
[TBL] [Abstract][Full Text] [Related]
31. BET Proteins Exhibit Transcriptional and Functional Opposition in the Epithelial-to-Mesenchymal Transition.
Andrieu GP; Denis GV
Mol Cancer Res; 2018 Apr; 16(4):580-586. PubMed ID: 29437854
[TBL] [Abstract][Full Text] [Related]
32. The BRD3 ET domain recognizes a short peptide motif through a mechanism that is conserved across chromatin remodelers and transcriptional regulators.
Wai DCC; Szyszka TN; Campbell AE; Kwong C; Wilkinson-White LE; Silva APG; Low JKK; Kwan AH; Gamsjaeger R; Chalmers JD; Patrick WM; Lu B; Vakoc CR; Blobel GA; Mackay JP
J Biol Chem; 2018 May; 293(19):7160-7175. PubMed ID: 29567837
[TBL] [Abstract][Full Text] [Related]
33. Functional intronic variant of SLC5A10 affects DRG2 expression and survival outcomes of early-stage non-small-cell lung cancer.
Hong MJ; Yoo SS; Choi JE; Kang HG; Do SK; Lee JH; Lee WK; Lee J; Lee SY; Cha SI; Kim CH; Lee EB; Cho S; Jheon S; Park JY
Cancer Sci; 2018 Dec; 109(12):3902-3909. PubMed ID: 30281872
[TBL] [Abstract][Full Text] [Related]
34. Stromal remodeling by the BET bromodomain inhibitor JQ1 suppresses the progression of human pancreatic cancer.
Yamamoto K; Tateishi K; Kudo Y; Hoshikawa M; Tanaka M; Nakatsuka T; Fujiwara H; Miyabayashi K; Takahashi R; Tanaka Y; Ijichi H; Nakai Y; Isayama H; Morishita Y; Aoki T; Sakamoto Y; Hasegawa K; Kokudo N; Fukayama M; Koike K
Oncotarget; 2016 Sep; 7(38):61469-61484. PubMed ID: 27528027
[TBL] [Abstract][Full Text] [Related]
35. BRD4 inhibition promotes TRAIL-induced apoptosis by suppressing the transcriptional activity of NF-κB in NSCLC.
Shi L; Xiong Y; Hu X; Wang Z; Xie C
Int J Med Sci; 2021; 18(14):3090-3096. PubMed ID: 34400879
[TBL] [Abstract][Full Text] [Related]
36. Potentially functional variants of HBEGF and ITPR3 in GnRH signaling pathway genes predict survival of non-small cell lung cancer patients.
Wu Y; Liu Z; Tang D; Liu H; Luo S; Stinchcombe TE; Glass C; Su L; Lin L; Christiani DC; Wang Q; Wei Q
Transl Res; 2021 Jul; 233():92-103. PubMed ID: 33400994
[TBL] [Abstract][Full Text] [Related]
37. BRD3-NUTM1-expressing NUT carcinoma of lung on endobronchial ultrasound-guided transbronchial needle aspiration cytology, a diagnostic pitfall.
Aryal SC; Zia S; Rodgers S; Shen Y; Perry K; Yuan L
Diagn Cytopathol; 2022 Feb; 50(2):E47-E53. PubMed ID: 34672128
[TBL] [Abstract][Full Text] [Related]
38. Acetylation of CCAR2 Establishes a BET/BRD9 Acetyl Switch in Response to Combined Deacetylase and Bromodomain Inhibition.
Rajendran P; Johnson G; Li L; Chen YS; Dashwood M; Nguyen N; Ulusan A; Ertem F; Zhang M; Li J; Sun D; Huang Y; Wang S; Leung HC; Lieberman D; Beaver L; Ho E; Bedford M; Chang K; Vilar E; Dashwood R
Cancer Res; 2019 Mar; 79(5):918-927. PubMed ID: 30643017
[TBL] [Abstract][Full Text] [Related]
39. Circular RNA circ_0074027 indicates a poor prognosis for NSCLC patients and modulates cell proliferation, apoptosis, and invasion via miR-185-3p mediated BRD4/MADD activation.
Gao P; Wang Z; Hu Z; Jiao X; Yao Y
J Cell Biochem; 2020 Mar; 121(3):2632-2642. PubMed ID: 31680319
[TBL] [Abstract][Full Text] [Related]
40. BET Inhibition as a Rational Therapeutic Strategy for Invasive Lobular Breast Cancer.
Walsh L; Haley KE; Moran B; Mooney B; Tarrant F; Madden SF; Di Grande A; Fan Y; Das S; Rueda OM; Dowling CM; Varešlija D; Chin SF; Linn S; Young LS; Jirström K; Crown JP; Bernards R; Caldas C; Gallagher WM; O'Connor DP; Ní Chonghaile T
Clin Cancer Res; 2019 Dec; 25(23):7139-7150. PubMed ID: 31409615
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
